openPR Logo
Press release

Bone Marrow Transplant Rejection - Pipeline Review, H2 2017

10-27-2017 01:06 PM CET | Health & Medicine

Press release from: ReportsWorldwide

Bone Marrow Transplant Rejection - Pipeline Review, H2 2017

Bone Marrow Transplant Rejection - Pipeline Review, H2 2017

ReportsWorldwide has announced the addition of a new report title Bone Marrow Transplant Rejection - Pipeline Review, H2 2017 to its growing collection of premium market research reports.

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Marrow Transplant Rejection - Pipeline Review, H2 2017, provides an overview of the Bone Marrow Transplant Rejection (Immunology) pipeline landscape.

Bone marrow transplant rejection is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient's body. Symptoms include chest pain, chills, drop in blood pressure, fever, flushing, funny taste in the mouth, headache, hives, nausea, pain and shortness of breath. Treatment includes immunosuppressive drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bone Marrow Transplant Rejection - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bone Marrow Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Bone Marrow Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 8, 22, 12, 47, 9 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3, 14 and 2 molecules, respectively.

Bone Marrow Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

To Enquire about this Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=41715

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Marrow Transplant Rejection (Immunology).
- The pipeline guide reviews pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bone Marrow Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bone Marrow Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bone Marrow Transplant Rejection (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bone Marrow Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

To view a detailed description and Table of Contents please visit: https://www.reportsworldwide.com/report/bone-marrow-transplant-rejection-pipeline-review-h2-2017

ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends. Moreover, ReportsWorldwide's Research Associates have in-depth knowledge of the reports and services on offer and are ready to provide assistance.

Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110
US
Phone +1 (617) 398-4994
Fax +1 (617) 398-4995
abigail@reportsworldwide.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Bone Marrow Transplant Rejection - Pipeline Review, H2 2017 here

News-ID: 790269 • Views:

More Releases from ReportsWorldwide

World Deep Brain Stimulation Market Top Segments, Key Players Revenue, Growth Ra …
The World Deep Brain Stimulation Market is estimated to represent a global market of USD 751.8 million by 2017 with growth rate of 18.2%. Deep brain stimulation (DBS) procedure is primarily used for the treatment of neuropsychiatric disorders such as mood disorder, dementia, anxiety and others. The procedure involve the use of neurotransmitter (brain pacemaker) that enables to transmit electric impulses to the specific target of brain cells. Increasing incidence
New report explores the Gene Editing Market : Ushering The Next Breakthrough in Regenerative Medicine
New report explores the Gene Editing Market : Ushering The Next Breakthrough in …
Boston, MA ReportsWorldwide has announced the addition of a new report title Gene Editing The Next Breakthrough in Regenerative Medicine to its growing collection of premium market research reports. Genome editing is a type of genetic engineering in which DNA is replaced, inserted or deleted in a living organism's ggenome using engineered molecular scissors. Believed to be one of the great biotechnology breakthroughs, gene editing is a powerful tool in pharmaceutical research that
Global In-Building Wireless BTSController-based Small Cells Market Analysis and Forecast, 2017-2021
Global In-Building Wireless BTSController-based Small Cells Market Analysis and …
Boston, MA ReportsWorldwide has announced the addition of a new report title Global In-Building Wireless BTSController-based Small Cells Market Analysis and Forecast, 2017-2021 to its growing collection of premium market research reports. This report covers the leading in-building wireless enterprise BTS/controller-based small cells network equipment manufacturers: • CommScope/Airvana • Comba Telecom • Ericsson • Huawei Technologies • Nokia • SpiderCloud • ZTE Corporation This report covers the global market share for 2016 shipments as well as a forecast for 2017-2021. To view a detailed description and Table of

More Releases for Bone

Bone Substitute And Allograft Bone Market Size, Scope, Growth, Competitive Analy …
Precision Business Insights published a research report on "Bone Substitutes and Bone Allografts Market By Product Type (Bone Substitutes and Bone Allografts), By Bone Substitute Type (Hydroxyapatite (Hap), Calcium Phosphate, Calcium Sulphate, Bioactive Glass), By Bone Allograft Type (Freeze Dried and Demineralized Bone Matrix) - Global/Region/Country Forecast to 2028" Bone grafts and substitutes are used to replace missing bones and to treat fractures. They are made up of an osteoconductive matrix
Bone Graft Substitute Market Report 2018: Segmentation by Type (autograft, demin …
Global Bone Graft Substitute market research report provides company profile for ACE Surgical Supply Company, Inc., BioHorizons IPH, Inc., Dentium Co., Ltd., Dentsply Sirona, Institut Straumann AG, Medtronic plc, Stryker Corporation, Zimmer Biomet and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and
Bone Implant Market Gaining Momentum Worldwide - CT-Bone, 3D printed Bone Implan …
Market Highlights Bone implant products are used in numerous orthopedic surgeries to support the bone and to restore the functionality of the bone. The increasing geriatric population, growing number of orthopedic surgical procedures, rising prevalence of sports-related injuries, and bone weakness due to the changing lifestyle are the major factors driving the growth of the global bone implant market. Additionally, aggressive strategies adopted by top players and increasing spending on healthcare
Bone Biopsy Market 2018 | Needle Biopsy | Open Biopsy | Bone Cancer | Bone Infec …
The Global Bone Biopsy Market is growing continuously and expected to grow at a CAGR of 5.7% from 2017 to 2023. Bone biopsy is performed to diagnose various bone disorders such as bone cancer, bone infection, osteoporosis and chronic kidney disease. Nowadays, biopsy procedure has received great importance in oncology as one of the promising methods in cancer diagnostics. The demand for needle biopsy is found to be increasing from
Bone Replacement Products Market– Effective Solution for Bone Problems
The innovative replacement systems are designed to provide patients with a joint preservation ultimatum, preserving the healthy parts of the knee, thus helping to maintain natural knee function. For instance, in 2014, Cayenne Medical launched the Mirror Partial Knee System, the only knee replacement system that uses the patient’s natural knee motion during the surgical procedure. This unique technology balances the knee throughout the entire range of motion. The
Global Bone Densitometry Market: By Product Type - X-Ray Bone Densitometry & Ult …
Researchmoz added Most up-to-date research on "Global Bone Densitometry Market: By Product Type - X-Ray Bone Densitometry & Ultrasonic Bone Densitometry" to its huge collection of research reports. In this report, the global Bone Densitometry market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented